The role of retroperitoneal lymph node dissection in the management of testicular cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 3, 2004, Pages 225-233

  Stephenson, Andrew J ^a   Sheinfeld, Joel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biological tumor markers; Combined modality therapy; Lymph node excision; Neoplasms, germ cell and embryonal blood drug therapy surgery; Retroperitoneal space; Seminoma; Testicular neoplasms drug therapy surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CHYLOUS ASCITES; CONFERENCE PAPER; EJACULATION DISORDER; FIBROSIS; FOLLOW UP; GERM CELL TUMOR; HEARING LOSS; HUMAN; IMAGING; INFERTILITY; INTESTINE OBSTRUCTION; KIDNEY DISEASE; LUNG CANCER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCELE; MORBIDITY; NECROSIS; ORCHIECTOMY; PERIOPERATIVE PERIOD; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; RELAPSE; RETROPERITONEAL DISEASE; RETROPERITONEUM; SCAR; SEMINOMA; SENSORY NEUROPATHY; SURGICAL TECHNIQUE; TERATOMA; TESTIS CANCER; TREATMENT FAILURE;

COMBINED MODALITY THERAPY; GERMINOMA; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROPERITONEAL SPACE; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 3242695249     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2004.04.029     Document Type: Conference Paper

References (119)

1. Einhorn L.H. Testicular cancer as a model for a curable neoplasm the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 41:1981;3275
2. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics, 2003. CA Cancer J Clin. 53:2003;5
3. Sheinfeld J. Nonseminomatous germ cell tumors of the testis current concepts and controversies. Urology. 44:1994;2
4. Donohue J.P., Zachary J.M., Maynard B.R. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol. 128:1982;315
5. Weinstein M. Lymphatic drainage of the testis. Atlas Urol Clin North Am. 7:1999;1
6. Sogani P.C. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. Urol Clin North Am. 18:1991;561
7. Whitmore W.F. Jr. Surgical treatment of adult germinal testis tumors. Semin Oncol. 6:1979;55
8. Hilton S., Herr H.W., Teitcher J.B., Begg C.B., Castellino R.A. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer assessment of size and distribution criteria. AJR Am J Roentgenol. 169:1997;521
9. Fernandez E.B., Moul J.W., Foley J.P., Colon E., McLeod D.G. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology. 44:1994;548
10. Donohue J.P., Thornhill J.A., Foster R.S., Rowland R.G., Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989) modifications of technique and impact on ejaculation. J Urol. 149:1993;237
11. Stephenson A.J., Bosl G.J., Motzer R.J., Stasi J., Bajorin D.F., Sheinfeld J. Impact of trends in patient selection for retroperitoneal lymph node dissection on retroperitoneal pathology and clinical outcome for patients with nonseminomatous germ cell tumor. 2004;. In preparation
12. Albers P., Siener R., Kliesch S., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors results of the German Testicular Cancer Study Group Trial. J Clin Oncol. 21:2003;1505
13. Heidenreich A., Sesterhenn I.A., Mostofi F.K., Moul J.W. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer. 83:1998;1002
14. Klepp O., Olsson A.M., Henrikson H., et al. Swedish-Norwegian Testicular Cancer Group. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis multivariate analysis of a prospective multicenter study. J Clin Oncol. 8:1990;509
15. Hermans B.P., Sweeney C.J., Foster R.S., Einhorn L.E., Donohue J.P. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol. 163:2000;1721
16. McLeod D.G., Weiss R.B., Stablein D.M., et al. Staging relationships and outcome in early stage testicular cancer a report from the Testicular Cancer Intergroup Study. J Urol. 145:1991;1178
17. Richie J.P. Clinical stage 1 testicular cancer the role of modified retroperitoneal lymphadenectomy. J Urol. 144:1990;1160
18. Sogani P.C., Perrotti M., Herr H.W., Fair W.R., Thaler H.T., Bosl G. Clinical stage I testis cancer long-term outcome of patients on surveillance. J Urol. 159:1998;855
19. Pizzocaro G., Zanoni F., Salvioni R., Milani A., Piva L., Pilotti S. Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis. J Urol. 138:1987;1393
20. Rorth M., Jacobsen G.K., von der Maase H., et al. Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. Danish Testicular Cancer Study Group. J Clin Oncol. 9:1991;1543
21. Sturgeon J.F., Jewett M.A., Alison R.E., et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol. 10:1992;564
22. Gels M.E., Hoekstra H.J., Sleijfer D.T., et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up a single-center 10-year experience. J Clin Oncol. 13:1995;1188
23. Pizzocaro G., Zanoni F., Milani A., et al. Retroperitoneal lymphadenectomy and aggressive chemotherapy in nonbulky clinical Stage II nonseminomatous germinal testis tumors. Cancer. 53:1984;1363
24. Donohue J.P., Thornhill J.A., Foster R.S., Rowland R.G., Bihrle R. Clinical stage B non-seminomatous germ cell testis cancer The Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer. 31A:1995;1599
25. Oldenburg J., Alfsen G.C., Lien H.H., Aass N., Waehre H., Fossa S.D. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 21:2003;3310
26. Toner G.C., Panicek D.M., Heelan R.T., et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors recommendations for patient selection. J Clin Oncol. 8:1990;1683
27. Baniel J., Foster R.S., Gonin R., Messemer J.E., Donohue J.P., Einhorn L.H. Late relapse of testicular cancer. J Clin Oncol. 13:1995;1170
28. George D.W., Foster R.S., Hromas R.A., et al. Update on late relapse of germ cell tumor a clinical and molecular analysis. J Clin Oncol. 21:2003;113
29. Bredael J.J., Vugrin D., Whitmore W.F. Jr. Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer. 50:1982;548
30. Sheinfeld J. Late recurrence of testicular cancer. AUA News. 6:2001;12
31. Sheinfeld J. Risks of the uncontrolled retroperitoneum. Ann Surg Oncol. 10:2003;100
32. Hesketh P.J., Krane R.J. Prognostic assessment in nonseminomatous testicular cancer implications for therapy. J Urol. 144:1990;1
33. Bosl G., Bajorin D., Sheinfeld J., Motzer R., Chaganti R.S.K. Cancer of the testis. DeVita V., Hellman S., Rosenberg S. Cancer principles and practice of oncology. 6 ed. :2001;1491-1518 JB Lippincott, Philadelphia
34. Freedman L.S., Parkinson M.C., Jones W.G., et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 2:1987;294
35. Read G., Stenning S.P., Cullen M.H., et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 10:1992;1762
36. Leibovitch I., Foster R.S., Kopecky K.K., Albers P., Ulbright T.M., Donohue J.P. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol. 16:1998;261
37. Pizzocaro G., Zanoni F., Milani A., et al. Orchiectomy alone in clinical stage I nonseminomatous testis cancer a critical appraisal. J Clin Oncol. 4:1986;35
38. Peckham M.J., Barrett A., Husband J.E., Hendry W.F. Orchidectomy alone in testicular stage I non-seminomatous germ-cell tumours. Lancet. 2:1982;678
39. Nicolai N., Miceli R., Artusi R., Piva L., Pizzocaro G., Salvioni R. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol. 171:2004;172
40. Swanson D.A., von Eschenbach A.C., Babaian R.J., Dinney C.P., Pisters L.L., Pettaway C.A. Is retroperitoneal lymph node dissection (RPLND) alone optimal or sufficient therapy for clinical stage I nonseminomatous germ cell testicular tumors (NSGCTT) at high risk for relapse? J Urol. 158:1998;179A
41. Pizzocaro G., Monfardini S. No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. J Urol. 131:1984;677
42. Rabbani F., Sheinfeld J., Farivar-Mohseni H., et al. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer pattern and prognostic factors for relapse. J Clin Oncol. 19:2001;2020
43. Williams S.D., Stablein D.M., Einhorn L.H., et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med. 317:1987;1433
44. Richie J.P., Kantoff P.W. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol. 9:1991;1393
45. Vogelzang N.J., Fraley E.E., Lange P.H., Torkelson J., Levitt S., Kennedy B.J. Stage II nonseminomatous testicular cancer a 10-year experience. J Clin Oncol. 1:1983;171
46. Javadpour N., Young J.D. Jr. Prognostic factors in nonseminomatous testicular cancer. J Urol. 135:1986;497
47. Kondagunta G.V., Sheinfeld J., Mazumdar M., et al. Relapse-free and overall survival in patients with pathologic stage ii nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol. 22:2004;464
48. Donohue J.P., Thornhill J.A., Foster R.S., Bihrle R., Rowland R.G., Einhorn L.H. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer the Indiana University experience (1965 to 1989). J Urol. 153:1995;85
49. Baniel J., Foster R.S., Einhorn L.H., Donohue J.P. Late relapse of clinical stage I testicular cancer. J Urol. 154:1995;1370
50. Amato R.J., Ro J.Y., Ayala A.G., Swanson D.A. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology. 63:2004;144
51. Bohlen D., Borner M., Sonntag R.W., Fey M.F., Studer U.E. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol. 161:1999;1148
52. Cullen M.H., Stenning S.P., Parkinson M.C., et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis a Medical Research Council report. J Clin Oncol. 14:1996;1106
53. Pont J., Albrecht W., Postner G., Sellner F., Angel K., Holtl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer long-term results of a prospective trial. J Clin Oncol. 14:1996;441
54. Oliver R.T., Raja M.A., Ong J., Gallagher C.J. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol. 148:1992;1453
55. Logothetis C.J., Samuels M.L., Trindade A., Johnson D.E. The growing teratoma syndrome. Cancer. 50:1982;1629
56. Motzer R.J., Amsterdam A., Prieto V., et al. Teratoma with malignant transformation diverse malignant histologies arising in men with germ cell tumors. J Urol. 159:1998;133
57. Sheinfeld J., Motzer R.J., Rabbani F., McKiernan J., Bajorin D., Bosl G.J. Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. J Urol. 170:2003;1159
58. Foster R.S., Baniel J., Leibovitch I., et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. J Urol. 155:1996;1943
59. Baniel J., Foster R.S., Rowland R.G., Bihrle R., Donohue J.P. Complications of primary retroperitoneal lymph node dissection. J Urol. 152:1994;424
60. Sheinfeld J. Complications of retroperitoneal lymph node dissection. AUA News. 7:2002;10
61. Bajorin D.F., Motzer R.J., Rodriguez E., Murphy B., Bosl G.J. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst. 85:1993;60
62. Huddart R.A., Norman A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 21:2003;1513
63. Bosl G.J., Motzer R.J. Testicular germ-cell cancer. N Engl J Med. 337:1997;242
64. Kollmannsberger C., Kuzcyk M., Mayer F., Hartmann J.T., Kanz L., Bokemeyer C. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol. 17:1999;275
65. Fossa S.D., Klepp O., Ous S., et al. Unilateral retroperitoneal lymph node dissection in patients with non-seminomatous testicular tumor in clinical stage I. Eur Urol. 10:1984;17
66. Donohue J.P., Foster R.S. Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am. 25:1998;461
67. Jewett M.A., Kong Y.S., Goldberg S.D., et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol. 139:1988;1220
68. Jewett M.A. Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol Clin North Am. 17:1990;449
69. Bhayani S.B., Ong A., Oh W.K., Kantoff P.W., Kavoussi L.R. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer a long-term update. Urology. 62:2003;324
70. Janetschek G., Hobisch A., Peschel R., Bartsch G. Laparoscopic retroperitoneal lymph node dissection. Urology. 55:2000;136
71. Nelson J.B., Chen R.N., Bishoff J.T., et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology. 54:1999;1064
72. Janetschek G. Laparoscopic retroperitoneal lymph node dissection. Urol Clin North Am. 28:2001;107
73. Pohar K.S., Rabbani F., Bosl G.J., Motzer R.J., Bajorin D., Sheinfeld J. Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. J Urol. 170:2003;1155
74. Davis B.E., Herr H.W., Fair W.R., Bosl G.J. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol. 152:1994;111
75. Saxman S.B., Nichols C.R., Foster R.S., Messemer J.E., Donohue J.P., Einhorn L.H. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol. 155:1996;587
76. Sheinfeld J., Rabbani F., Farivar-Mohseni H., et al. Elevated serum tumor markers prior to primary RPLND predicts clinical outcome and requirements for systemic chemotherapy in patients with PN1, N2 and N3 nonseminomatous germ cell tumor. Proc Am Soc Clin Oncol. 18:1999;1184A
77. Socinski M.A., Garnick M.B., Stomper P.C., Fung C.Y., Richie J.P. Stage II nonseminomatous germ cell tumors of the testis an analysis of treatment options in patients with low volume retroperitoneal disease. J Urol. 140:1988;1437
78. Pizzocaro G., Piva L., Salvioni R., Pasi M., Pilotti S., Monfardini S. Adjuvant chemotherapy in resected stage-II nonseminomatous germ cell tumors of testis. In which cases is it necessary? Eur Urol. 10:1984;151
79. Motzer R.J., Bosl G.J. Role of adjuvant chemotherapy in patients with stage II nonseminomatous germ-cell tumors. Urol Clin North Am. 20:1993;111
80. Sheinfeld J., Bajorin D. Management of the postchemotherapy residual mass. Urol Clin North Am. 20:1993;133
81. Bajorin D.F., Herr H., Motzer R.J., Bosl G.J. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. Semin Oncol. 19:1992;148
82. Donohue J.P., Einhorn L.H., Williams S.D. Cytoreductive surgery for metastatic testis cancer considerations of timing and extent. J Urol. 123:1980;876
83. Fossa S.D., Qvist H., Stenwig A.E., Lien H.H., Ous S., Giercksky K.E. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol. 10:1992;569
84. Donohue J.P., Leviovitch I., Foster R.S., Baniel J., Tognoni P. Integration of surgery and systemic therapy results and principles of integration. Semin Urol Oncol. 16:1998;65
85. Steyerberg E.W., Gerl A., Fossa S.D., et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol. 16:1998;269
86. Stenning S.P., Parkinson M.C., Fisher C., et al. Postchemotherapy residual masses in germ cell tumor patients content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer. 83:1998;1409
87. International Germ Cell Consensus Classification. A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 15:1997;594
88. Patel M.I., Beck S., Bosl G.J., Motzer R., Bajorin D., Sheinfeld J. Histology of goor risk non-seminomatous germ cell tumor patients following postchemotherapy retroperitoneal lymph node dissection after four cycles of etoposide and cisplatin. J Urol. 169:2003;681A
89. Fox E.P., Weathers T.D., Williams S.D., et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol. 11:1993;1294
90. Little J.S. Jr, Foster R.S., Ulbright T.M., Donohue J.P. Unusual neoplasms detected in testis cancer patients undergoing post-chemotherapy retroperitoneal lymphadenectomy. J Urol. 152:1994;1144
91. Comiter C.V., Kibel A.S., Richie J.P., Nucci M.R., Renshaw A.A. Prognostic features of teratomas with malignant transformation a clinicopathological study of 21 cases. J Urol. 159:1998;859
92. Lutke Holzik M.F., Hoekstra H.J., Mulder N.H., Suurmeijer A.J., Sleijfer D.T., Gietema J.A. Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor. Ann Surg Oncol. 10:2003;131
93. Donadio A.C., Motzer R.J., Bajorin D.F., et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol. 21:2003;4285
94. Borge N., Fossa S.D., Ous S., Stenwig A.E., Lien H.H. Late recurrence of testicular cancer. J Clin Oncol. 6:1988;1248
95. Gelderman W.A., Scraffordt Koops H., Sleijfer D.T., Oosterhuis J.W., Oldhoff J. Late recurrence of mature teratoma in nonseminomatous testicular tumors after PVB chemotherapy and surgery. Urology. 33:1989;10
96. Loehrer P.J. Sr, Hui S., Clark S., et al. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors a clinicopathological correlation. J Urol. 135:1986;1183
97. Richie J.P., Garnick M.B., Finberg H. Computerized tomography how accurate for abdominal staging of testis tumors? J Urol. 127:1982;715
98. Stomper P.C., Jochelson M.S., Garnick M.B., Richie J.P. Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer correlation of CT and histology. AJR Am J Roentgenol. 145:1985;743
99. Fossa S.D., Stenwig A.E., Lien H.H., Ous S., Kaalhus O. Non-seminomatous testicular cancer clinical stage I prediction of outcome by histopathological parameters. A multivariate analysis. Oncology. 46:1989;297
100. Donohue J.P., Rowland R.G., Kopecky K., et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol. 137:1987;1176
101. Debono D.J., Heilman D.K., Einhorn L.H., Donohue J.P. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol. 15:1997;1455
102. Beck S.D., Foster R.S., Bihrle R., et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol. 168:2002;1402
103. Steyerberg E.W., Keizer H.J., Fossa S.D., et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor multivariate analysis of individual patient data from six study groups. J Clin Oncol. 13:1995;1177
104. Vergouwe Y., Steyerberg E.W., Foster R.S., Habbema J.D., Donohue J.P. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. J Urol. 165:2001;84
105. Motzer R.J., Bajorin D.F., Vlamis V., Weisen S., Bosl G.J. Ifosfamide-based chemotherapy for patients with resistant germ cell tumors the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol. 19:1992;8
106. Shahidi M., Norman A.R., Dearnaley D.P., Nicholls J., Horwich A., Huddart R.A. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer. 95:2002;520
107. Baniel J., Foster R.S., Rowland R.G., Bihrle R., Donohue J.P. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol. 153:1995;976
108. Coogan C.L., Hejase M.J., Wahle G.R., et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol. 156:1996;1656
109. Wood D.P. Jr, Herr H.W., Motzer R.J., et al. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer. 70:1992;2354
110. Eastham J.A., Wilson T.G., Russell C., Ahlering T.E., Skinner D.G. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology. 43:1994;74
111. Murphy B.R., Breeden E.S., Donohue J.P., et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol. 11:1993;324
112. Foster R.S., Donohue J.P. Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? Urol Clin North Am. 25:1998;479
113. McKiernan J.M., Motzer R.J., Bajorin D.F., Bacik J., Bosl G.J., Sheinfeld J. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor clinical presentation, patterns of recurrence, and outcome. Urology. 62:2003;732
114. Sheinfeld J., McKiernan J., Bosl G.J. Surgery of testicular tumors. Walsh P.C., Retik A.B., Vaughn E.D., Wein A.J. 8th ed. Campbell's urology. 3:2002;2920-2944 WB Saunders, Philadelphia
115. Loehrer P.J. Sr, Birch R., Williams S.D., Greco F.A., Einhorn L.H. Chemotherapy of metastatic seminoma the Southeastern Cancer Study Group experience. J Clin Oncol. 5:1987;1212
116. Fossa S.D., Borge L., Aass N., Johannessen N.B., Stenwig A.E., Kaalhus O. The treatment of advanced metastatic seminoma experience in 55 cases. J Clin Oncol. 5:1987;1071
117. Herr H.W., Sheinfeld J., Puc H.S., et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol. 157:1997;860
118. Puc H.S., Heelan R., Mazumdar M., et al. Management of residual mass in advanced seminoma results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 14:1996;454
119. De Santis M., Becherer A., Bokemeyer C., et al. FDG-PET as prognostic indicator for seminoma residuals an update from the multicenter SEMPET study. Proc Am Soc Clin Oncol. 22:2003;1535A